Abcam, ab258121, Human PLAA knockout HeLa cell lysate

Size: 1Kit
PLAA KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Insertion of the selection cassette in exon3.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Insertion of the selection cassette in exon3.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PLAA, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Phospholipase A2 activator protein (PLAP) also known as phospholipase A facilitates the activation of phospholipase A2 enzymes. PLAP assists in the release of arachidonic acid from phospholipids within cellular membranes. The protein is approximately 30 kDa in mass and expresses widely in various tissues including liver and brain. Researchers frequently study PLAP to understand its role in modulating lipid signaling pathways.
Biological function summary
This protein actively participates in cellular responses by modulating the production of lipid mediators. PLAP does not work standalone; it forms part of the calcium-dependent phospholipid-binding complex. Through its role in this complex it influences numerous processes such as inflammation and immune response. PLAP is also essential for the optimal function of inflammatory cell membranes by regulating the release of pro-inflammatory eicosanoids.
Pathways
This protein contributes significantly to the arachidonic acid metabolism pathway and eicosanoid biosynthesis pathway. In these pathways PLAP ensures the effectiveness of phospholipase A2 enabling the release of arachidonic acid a precursor for prostaglandins and leukotrienes. These components influence key activities in cellular signaling. Proteins such as cyclooxygenase (COX) and lipoxygenase follow through these pathways affecting cellular responses.
Alterations in PLAP activity relate to inflammatory conditions such as asthma and arthritis. The protein's role in the overproduction of eicosanoids connects it to the inflammation seen in these diseases. Another protein cyclooxygenase-2 (COX-2) also plays a significant part in these conditions acting downstream in the arachidonic acid pathway to produce inflammatory mediators. This link makes PLAP a significant target for therapeutic intervention in managing inflammation-related diseases.